Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder

Robert L. Findling, Michael D. Reed, Mary Ann O'Riordan, Christine A. Demeter, Robert J. Stansbrey, Nora K. McNamara

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To provide an initial description of the effectiveness and pharmacokinetics (PK) of quetiapine in aggressive children with conduct disorder (CD). METHOD: This 8-week, open-label outpatient trial, enrolled patients ages 6 to 12 years with CD. Outcome measures included the Rating of Aggression Against People and/or Property Scale (RAAPPS), Nisonger Child Behavior Rating Form (NCBRF), and the Conners Parent Rating Scale (CPRS-48). Blood sampling for PK analyses occurred at the end of weeks 2 and 8. RESULTS: Seventeen children (16 boys, mean age 8.9 years) were treated. The mean dose at week 8 was 4.4 mg/kg (SD = 1.1 mg/kg). Significant decreases in the baseline scores of the RAAPPS, and several subscales of the NCBRF and the CPRS were found by the end of the study (p <.05). No patients discontinued because of an adverse event. No patients experienced extrapyramidal side effects. Quetiapine disposition was linear over the dose range studied. The elimination half-life of the drug averaged 3.9 and 2.9 hours and total body clearance averaged 3.5 and 3.0 L/hr/kg after study weeks 2 and 8, respectively. CONCLUSIONS: These preliminary data suggest that aggressive children with CD may benefit from quetiapine. The PK of quetiapine supports twice-daily dosing in children with CD.

Original languageEnglish (US)
Pages (from-to)792-800
Number of pages9
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume45
Issue number7
DOIs
StatePublished - Jul 1 2006
Externally publishedYes

Keywords

  • Aggression
  • Children
  • Conduct disorder
  • Pharmacokinetics
  • Quetiapine

ASJC Scopus subject areas

  • Developmental and Educational Psychology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder'. Together they form a unique fingerprint.

  • Cite this